PFAS REACH Restriction
The universal PFAS restriction proposal submitted in January 2023 by Germany, the Netherlands, Denmark, Norway and Sweden to ECHA under REACH is the largest chemical restriction in EU history. It targets the entire PFAS chemical class — an estimated 10,000+ substances — across virtually every industrial use. ECHA's Risk Assessment Committee (RAC) and Socio-Economic Analysis Committee (SEAC) opinion is expected to conclude in 2025-2026, with a Commission adoption likely in 2026-2027 and use-by-use transition periods of 18 months to 13.5 years.
01What PFAS are — and the OECD class definition
Per- and polyfluoroalkyl substances (PFAS) are a class of synthetic chemicals containing at least one fully fluorinated methyl or methylene carbon. The 2021 OECD definition — 'any substance that contains at least one fully fluorinated methyl (CF3-) or methylene (-CF2-) carbon atom (without any H/Cl/Br/I atom attached to it)' — is the technical reference the restriction uses. By that definition there are at least 10,000 substances and probably tens of thousands more.
PFAS persist in the environment essentially indefinitely (hence 'forever chemicals'), bioaccumulate in many cases, and several PFAS have established toxicity (PFOA, PFOS, PFHxS, GenX, PFHxA). The 5-State proposal applies the class concept on the precautionary principle: regulate the class because the case-by-case regulation of individual PFAS has consistently lagged science and emissions.
02Scope of the proposed restriction
The proposal would restrict the manufacture, placing on the market and use of PFAS in the EU/EEA, with derogations for specific uses where alternatives are not available, the socio-economic benefits outweigh the risks and emissions are minimised. The default would be 'no PFAS' unless a use falls within a derogation.
- Manufacture in EU/EEA
- Placing on the EU/EEA market
- Use (including as a process aid, processing aid, intermediate, in articles, in mixtures)
- Imports of articles containing PFAS
- Exports — manufacture for export is partly addressed by parallel Commission proposals on the EU Chemicals Strategy
03Derogations and transition periods
The proposal includes a long list of use-specific derogations with transition periods of 18 months, 5 years, 12 years or 13.5 years depending on the maturity of alternatives. The RAC and SEAC consultations are refining these. Indicative categories under discussion:
| Use category | Indicative transition |
|---|---|
| Consumer mixtures (cosmetics, ski wax, certain textiles) | 18 months |
| Food contact materials (most) | 5 years |
| Medical devices (most), excipients in drug products | 5-13.5 years depending on criticality |
| Semiconductor manufacture | 12 years (case-specific) |
| F-gas refrigerants, fluoropolymers in fuel cells, hydrogen technology | 12 years |
| Fluoropolymer membranes in batteries / electrolysers / chlor-alkali | 12 years |
| Pharmaceutical APIs containing CF3 / CF2 groups | Active dossier discussion — derogation likely but not finalised |
04Timeline and process
- January 2023 — Annex XV proposal submitted by Germany, Netherlands, Denmark, Norway, Sweden.
- March-September 2023 — six-month public consultation; 5,600+ comments received.
- 2024-2026 — RAC opinion (risk) and SEAC opinion (socio-economic) developed in tranches by use category.
- 2026 — combined opinion delivered to the European Commission.
- 2026-2027 — Commission proposal for restriction (REACH Annex XVII amendment) and co-decision.
- Adoption + transition periods — varies by use; the earliest use-category bans likely 2027-2028.
05Operational impact — across sectors
PFAS are pervasive: fluoropolymer process equipment (PTFE / FEP / PFA seals, gaskets, tubing), water- and oil-repellent textiles, ski wax, cosmetics, food-contact paper coatings, semiconductor manufacturing (lithography, etching, immersion fluids), medical devices (catheters, implant coatings, drug-delivery membranes), pharmaceutical APIs (fluorinated drug substances), refrigerants, fire-fighting foams (AFFF — already largely phased out under separate measures), aviation hydraulic fluids and many more.
The hardest hit categories are those where no alternative exists (high-purity semiconductor process chemicals; many medical-device polymers; certain pharmaceutical APIs) and those where alternatives exist but qualification cycles are long (pharmaceutical excipients, medical-device coatings).
06Global context
- United States — EPA has restricted specific PFAS (PFOS / PFOA / GenX in drinking water); state-level bans (Maine, Minnesota, New York) on PFAS in specified product categories.
- Stockholm Convention — PFOS, PFOA, PFHxS listed for elimination; PFHxS-related compounds added 2022.
- Canada — proposed group-based PFAS approach; 2024 State of PFAS Report
- UK — Health and Safety Executive RMOA on PFAS, separate from the EU restriction but informed by it.
- China, India — sector-specific restrictions on individual PFAS.
07What operators should do now
- Inventory PFAS in raw materials, process aids, equipment elastomers and packaging — including legacy materials and trace contaminants.
- Engage suppliers for full PFAS disclosure (substance identity, concentration, function, derogation alignment).
- Identify candidate alternatives and start qualification — for regulated sectors the qualification timeline can exceed the transition period.
- Quantify and reduce emissions now — RAC consistently expects 'minimisation of emissions' even within derogations.
- Track RAC and SEAC opinion tranches per use category — early signals on the final scope and dates.
- Plan multi-region — US state-level bans (Maine 2030 / Minnesota 2032 / etc.) may force action earlier than the EU transition.
08How V5 supports PFAS transition
09Common pitfalls
- Assuming fluoropolymers are out of scope — polymers of low concern have been discussed but the default position is that all PFAS-class substances are in scope.
- Underestimating PFAS in equipment (PTFE-lined vessels, FKM/FFKM seals, PFA tubing) and in trace process residues.
- Treating derogation as a permanent licence — every derogation comes with emissions-minimisation expectations.
- Single-substance substitution to another PFAS — fails the class-based approach.
- Waiting for the final restriction text before starting qualification — most qualification cycles exceed the transition periods.
Frequently asked questions
Q.Are fluoropolymers (PTFE, PFA, FEP) in scope?+
By the OECD definition, yes — they fall within the PFAS class. There is active discussion of differentiating 'polymers of low concern' but the default proposal includes them.
Q.When does the restriction take effect?+
There is no single date. Adoption is expected 2026-2027, with use-specific transition periods of 18 months to 13.5 years from entry into force.
Q.What about pharmaceutical fluorinated APIs?+
Many marketed drugs contain CF3 groups (atorvastatin, sitagliptin, sofosbuvir, etc.). The proposal acknowledges the criticality and likely derogation for medicinal products; the exact mechanics are under negotiation.
Q.Does this affect non-EU manufacturers?+
Yes — placing PFAS-containing products on the EU market or importing articles containing PFAS is in scope regardless of where the product is manufactured.
Primary sources
Further reading
V5 Ultimate ships with the PFAS REACH Restriction controls already wired in — audit trail, e-signatures, validation evidence. Free trial, no credit card, onboard in days, not months.